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Background: Obstructive sleep apnea (OSA) has both systemic and local effects partly through
the increased oxidative stress caused by intermittent hypoxia and reoxygenation. However,
lung-specific biomarkers in OSA have not been fully assessed in comparison with systemic
biomarkers such as C-reactive protein (CRP), although results of a recent study having a small
sample size indicated KL-6 as one candidate.
Methods: Subjects of the present study were 197 patients suspected to have OSA. In addition
to polysomnography, we also measured serum levels of KL-6, surfactant protein-D (SP-D) and
CRP and pulmonary function. We examined the relationships of different biomarkers with
OSA severity and pulmonary function.
Results: The apnea/hypopnea index (AHI) was significantly positively correlated with serum
KL-6 levels even after adjustment for body mass index (BMI) and smoking (p Z 0.03), but
not with SP-D and CRP. Also, a significant trend for an increase in serum KL-6 was noted in
accordance with the severity of OSA even after adjustment for BMI and smoking (b
coefficientZ 0.18, pZ 0.02). Additionally, elevated KL-6 levels were significantly associated
with restrictive lung function disturbance and gas exchange derangement after adjustment for
obesity and smoking, which contrasted with CRP whose elevations were significantly associ-
ated with worsened airflow limitation and increased lung volume.
Conclusions: Serum KL-6 levels may reflect the degree of subclinical lung injury associated
with OSA independently of obesity or smoking, unlike CRP. We consider that KL-6 can be
a potential candidate as a lung-specific biomarker of OSA and might provide complementary
information on systemic biomarkers in assessing OSA.
ª 2011 Elsevier Ltd. All rights reserved.751 3852; fax: þ81 75 751 3854.
-u.ac.jp (T. Oga).
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Obstructive sleep apnea (OSA) is characterized by repeated
episodes of upper airway obstruction accompanied by
intermittent hypoxia and reoxygenation, which can cause
oxidative stress.1 It contributes not only to endothelial
dysfunction in the peripheral circulation, but possibly also
contributes to epithelial and endothelial cell injury in the
alveolus causing increased alveolar wall permeability in the
lungs.2,3
KL-6 is a mucin-like glycoprotein with a molecular
weight of 200 kd and is mainly expressed on alveolar type II
and bronchiolar epithelial cells in human lungs.4 Elevated
levels of circulating KL-6 have been reported in patients
with lung injury.5,6 Recently, Lederer et al. reported that
circulating levels of KL-6 were elevated in some patients
with OSA in association with greater endothelial dysfunc-
tion, suggesting that subclinical lung injury may be present
in OSA.7 However, the sample size in that study was very
small, comprising only 11 OSA patients and 10 controls, and
the relationships of elevated levels of KL-6 with other
biomarkers or pulmonary function were not examined.
Therefore, the role of KL-6 as a biomarker of lung injury in
OSA has not been fully elucidated.
In addition to KL-6, circulating levels of surfactant
protein-D (SP-D) are elevated in patients with lung injury.8,9
SP-D is also exclusively produced by alveolar type II cells in
the lungs and its values change with the clinical status of
patients or with relevant exposures.10 Therefore, recently,
much attention has been paid to SP-D as a potential lung-
specific biomarker in diseases such as chronic obstructive
pulmonary disease (COPD) where both local and systemic
inflammation play respective important roles in disease
progression.10,11 In OSA, increased levels of various
systemic inflammatory biomarkers, including C-reactive
protein (CRP), tumor necrosis factor-a, interleukin-6, and
interleukin-8, have been reported to be associated with
future cardiovascular risk.12 Considering that OSA has
respiratory and systemic effects, a lung-specific blood
biomarker would be attractive and informative.
We hypothesized that higher serum levels of KL-6 and
SP-D would be associated with more severe OSA and more
severe impairments in pulmonary function, reflecting the
degree of subclinical lung injury unlike CRP, which is the
most widely studied systemic biomarker in OSA.12 Although
the magnitude of the injury might not be great, it may not
only cause respiratory symptoms such as chronic cough13
but also may worsen other possible comorbid disorders
such as asthma,14 COPD15 or idiopathic pulmonary fibrosis
(IPF).16 Therefore, in the present study, we examined the
relationships between these three different biomarkers,




A total of 197 patients were consecutively recruited from
the Sleep Unit of Kyoto University Hospital between April
2009 and April 2010. All had been referred to our sleep unitwith symptoms such as habitual snoring or daytime sleepi-
ness. None had been previously diagnosed with or treated
for OSA. Patients with pulmonary diseases such as asthma
(nZ 14), COPD (nZ 5) or interstitial lung diseases (nZ 2)
and who were diagnosed as having central sleep apnea
(n Z 6) were excluded based on clinical history, spirom-
etry, chest radiograph and polysomnography, and a total of
170 patients were examined further. This study was
approved by the Kyoto University Graduate School and
Faculty of Medicine Ethics Committee, and informed
consent was obtained from all patients. Arterial blood gas
analysis, including arterial partial tension of oxygen (PaO2)
and arterial partial tension of carbon dioxide (PaCO2), was
performed while patients were breathing room air at rest in
the supine position. The alveolar-arterial oxygen tension
difference (A-aDO2) was calculated according to the stan-
dard formula, using the respiratory exchange ratio of 0.8.Polysomnography
The diagnosis of OSA was confirmed by polysomnography
(SomnoStar pro, Cardinal Health, Dublin, OH, USA), which
was started at 22:00 and ended at 6:00 the following
morning. Surface electrodes were attached using standard
techniques to obtain an electrooculogram, electromyogram
of the chin, and 12-lead electroencephalograph. Sleep
stages were defined according to the criteria of
Rechtschaffen and Kales.17 Ventilation was monitored by
inductive plethysmography (Respitrace QDC, Viasys
Healthcare, Palm Springs, CA, USA). Airflow was monitored
by a nasal pressure transducer (PTAFlite, Pro-Tech Services
Inc., Mukilteo, WA, USA) and supplemented by an oronasal
thermal sensor (Sleepmate Technologies, Midlothian, VA,
USA). Arterial oxygen saturation (SpO2) was monitored
continuously with a pulse oximeter (Adult Flex System,
Nonin Medical, Plymouth, MN, USA).
Apnea was defined as the complete cessation of airflow
and hypopnea as a clear decrease in airflow of 50% or more
lasting for 10 s or more accompanied by a decrease in SpO2
of at least 3%.18 All AHI values were expressed as the
number of episodes of apnea and hypopnea per hour over
the total sleep time. The lowest SpO2 during sleep was
calculated in each patient. OSA severity was defined by the
AHI as follows: non OSA (AHI<5), mild OSA (5  AHI<15),
moderate OSA (15  AHI<30) and severe OSA (30  AHI).Blood sample collection and measurements of
serum biomarkers levels
Following overnight polysomnography, samples of periph-
eral venous blood were collected in the morning after an
overnight fast. Serum KL-6 levels were measured by
a sandwich-type electrochemiluminescence immunoassay
kit (Picolumi KL-6; Sanko Junyaku, Tokyo, Japan), serum
SP-D levels were measured by a sandwich-type enzyme
immunoassay kit (SP-D kit Yamasa EIA II; Yamasa Shoyu,
Chiba, Japan), and serum CRP levels were measured using
a high sensitive assay kit (N-Assay LA CRP-S kit; Nittobo
Medical, Tokyo, Japan).
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Pulmonary function tests were performed using CHESTAC
(Chest M.I. Inc., Tokyo, Japan). Residual volume (RV) and
total lung capacity (TLC) were measured by the closed-
circuit helium method, and diffusing capacity for carbon
monoxide (DLCO) was measured using a single-breath
technique. Percent-predicted values were used for
analyses.
Statistics
All statistical analyses were performed using StatView
version 5.0 for Windows (Abacus Concepts, Berkeley, CA,
USA). Continuous variables are expressed as
means  standard deviation (SD). The unpaired t-test was
used to compare AHI levels between men and women. The
significance of intergroup differences based on the severity
of OSA was determined by an analysis of variance (ANOVA).
When a significant difference was observed, we used the
Fisher’s PLSD method to identify where the differences
were significant. A chi-square test was used to compare
dichotomous variables. Relationships between 2 variables
were analyzed by Pearson’s correlation coefficient tests.
The trend of serum biomarker levels across OSA groups was
examined by two models. Model 1 is a linear model with
serum biomarker levels as the dependent variable and with
three indicator variables for mild, moderate, and severe
OSA as the independent variables. We reported the b coef-
ficients for the three OSA variables as mean differences in
biomarker levels versus the non OSA group (reference).
Model 2 is also a linear model wherein the indicator vari-
ables are replaced with a single ordinal variable equal to
the median AHI in the mild, moderate and severe OSA
groups, respectively and 0 in the non OSA group. Multiple
regression analyses were performed to adjust for the
confounders. A p value less than 0.05 was considered to
indicate statistical significance.
Results
Relationships of clinical indices and serum
biomarker levels to AHI
Patient characteristics and polysomnographic data are
shown in Table 1. The study group of 170 patients was
comprised of 20 non OSA, 25 mild OSA, 52 moderate OSA
and 73 severe OSA patients. Significant differences were
observed in sex, age, body mass index (BMI) and smoking
among the groups. Serum KL-6 levels were also significantly
different among the groups (p Z 0.04), but not SP-D
(p Z 0.65) or CRP (p Z 0.53). There were significant
differences among the groups in PaO2 and A-aDO2.
We investigated the relationships between subjects’
background, serum biomarker levels and AHI. With regard
to clinical characteristics, the AHI was not significantly
different between men and women (p Z 0.12), and had
significant positive correlations with BMI [r (correlation
coefficient) Z 0.50, p < 0.001] and smoking (r Z 0.23,
p Z 0.003), but not with age (r Z 0.06, p Z 0.44). On theother hand, the AHI had a significant positive correlation
with serum levels of KL-6 (r Z 0.20, p Z 0.01) and CRP
(rZ 0.17, pZ 0.03), although a significant correlation was
not found between the AHI and serum levels of SP-D
(r Z 0.06, p Z 0.48). After adjustment for BMI and
smoking, which were significantly associated with the AHI
as mentioned above, the correlation of the AHI with serum
KL-6 levels remained weak but statistically significant (b
coefficient Z 0.14, p Z 0.03), whereas its correlation
with serum CRP levels was far from significant (b
coefficient Z 0.00, p Z 0.97).
Table 2 shows trends of serum biomarker levels across
OSA groups. A significant trend for an increase in serum
KL-6 levels was noted in accordance with the severity of
OSA even after adjustment for BMI and smoking (b
coefficient Z 0.18, p Z 0.02 for both Model 1 and 2),
whereas no significant trend was found in serum levels of
SP-D and CRP.
As to the lowest SpO2, no significant relationships with
serum levels of KL-6, SP-D and CRP were found. Regarding
the inter-relationships among the three serum biomarkers
examined, there was a significant correlation between
serum levels of KL-6 and SP-D (r Z 0.24, p Z 0.002), but
serum CRP levels did not correlate with either KL-6 or SP-D
levels.
Relationships of pulmonary function and arterial
blood gas data to serum biomarker levels
Next, to assess the clinical relevance of KL-6 and CRP,
which were significantly related to AHI, we compared their
relationships with pulmonary function and arterial blood
gas data. After adjustment for BMI and smoking, serum KL-6
levels were significantly positively correlated with A-aDO2
and negatively correlated with vital capacity (VC), forced
vital capacity (FVC), TLC and DLCO (Table 3). In contrast,
serum CRP levels were significantly positively correlated
with TLC and negatively correlated with forced expiratory
volume in 1 s (FEV1) (Table 3).
Discussion
We analyzed the inter-relationships of different serum
biomarkers with OSA and pulmonary function. We found
that, after adjustment for obesity and smoking, the serum
KL-6 levels significantly correlated with the AHI, unlike
serum levels of SP-D and CRP. Additionally, elevated serum
KL-6 levels were significantly associated with increased A-
aDO2 and decreased VC, FVC, TLC and DLCO even after
adjustment for obesity and smoking, whereas elevated
serum CRP levels were significantly associated with
increased TLC and decreased FEV1.
Our results indicate the significance of circulating
levels of KL-6 as a marker of lung injury associated with
OSA. Although Lederer et al. reported elevated circulating
levels of KL-6 in some patients with OSA in comparison
with controls in a study having a small sample size,7 we
expanded knowledge in this area by confirming the
significant relationship between serum KL-6 levels and the
severity of OSA with a relatively large number of subjects
and, in addition, compared values for serum KL-6 with
Table 1 Clinical characteristics and polysomnographic data on 170 patients.
non OSA (n Z 20) mild OSA (n Z 25) moderate OSA (n Z 52) severe OSA (n Z 73) p value
Sex (male/female) 12/8 16/9 37/15 62/11a,c 0.04
Age (years) 43.6  17.7 56.7  15.7a 57.5  15.6a 57.3  13.5a 0.003
BMI (kg/m2) 24.8  3.4 25.7  4.1 25.6  5.3 28.7  6.1a,b,c 0.002
Smoking history
(current/ex/never)
12/6/2 9/9/7 26/18/8 18/39/16a,c 0.02
Smoking (pack years) 5.4  12.7 18.0  23.3 21.1  34.2a 28.3  30.9a 0.02
Serum KL-6 (U/ml) 198.7  56.0 227.2  90.0 246.8  117.1 285.7  170.8a 0.04
Serum SP-D (ng/ml) 41.6  26.4 48.4  22.3 53.0  43.7 51.9  36.1 0.65
Serum CRP (mg/dl) 0.14  0.27 0.20  0.40 0.13  0.22 0.21  0.32 0.53
AHI (events/hour) 2.2  1.5 9.8  2.8 22.1  4.3a,b 54.3  21.6a,b,c <0.0001
Lowest SpO2 (%) 89.7  6.4 84.4  8.3 80.3  11.3a 73.9  9.3a,b,c <0.0001
VC (% predicted) 107.3  13.3 107.8  19.0 113.0  15.5 110.6  17.4 0.46
ERV (% predicted) 82.8  26.1 81.6  36.9 83.1  38.5 71.1  35.8 0.23
FVC (% predicted) 107.7  14.0 105.4  19.7 111.8  16.3 108.5  17.9 0.46
FEV1 (% predicted) 99.4  13.6 98.9  20.7 107.2  15.5 106.3  17.9 0.10
FRC (% predicted) 106.9  24.4 103.2  30.2 111.5  47.9 125.4  41.9 0.71
RV (% predicted) 108.4  37.6 113.2  38.9 104.9  26.9 106.4  41.2 0.81
TLC (% predicted) 95.3  13.8 102.0  25.9 99.3  18.9 96.6  15.4 0.50
DLCO (% predicted) 89.4  15.7 82.0  17.3 81.1  19.3 85.7  15.1 0.21
PaCO2 (kPa) 5.7  0.5 5.6  0.5 5.7  0.5 5.6  0.6 0.61
PaO2 (kPa) 12.0  1.7 11.6  1.7 11.5  1.4 10.9  1.6a,c 0.01
A-aDO2 (kPa) 0.9  1.7 1.5  1.6 1.3  0.4 2.1  1.5a,c 0.003
Data presented as number or mean  SD.
a p < 0.05 versus non OSA.
b p < 0.05 versus mild OSA.
c p < 0.05 versus moderate OSA. OSA: obstructive sleep apnea; BMI: body mass index; SP-D: surfactant protein-D; CRP: C-reactive
protein; AHI: apnea/hypopnea index; VC: vital capacity; ERV: expiratory reserve volume; FVC: forced vital capacity; FEV1: forced
expiratory volume in 1 s; FRC: functional residual capacity; RV: residual volume; TLC: total lung capacity; DLCO: diffusing capacity for
carbon monoxide; PaCO2: arterial partial tension of carbon dioxide; PaO2: arterial partial tension of oxygen; A-aDO2: alveolar-arterial
oxygen tension difference.
942 K. Aihara et al.other potential biomarkers. Moreover, elevated KL-6
levels were also significantly associated with restrictive
lung function disturbance and gas exchange derangement,
which are characteristic features in lung injury. Lederer
et al. speculated that the possible mechanisms whereby
OSA leads to lung injury include chronic oxidative stress
associated with repeated intermittent hypoxia and reox-
ygenation and mechanical stretch caused by dynamic
changes in intrathoracic pressure.7 In addition to these
factors, snoring-induced vibratory force might be aTable 2 Trends of serum biomarker levels across OSA groups.
Model 1
Unadjusted Adj
Serum KL-6 (U/ml) b Z 0.22 b Z
p Z 0.004 p Z
Serum SP-D (ng/ml) b Z 0.08 b Z
p Z 0.28 p Z
Serum CRP (mg/dl) b Z 0.06 b Z
p Z 0.41 p Z
Model 1: Linear model with three indicator variables for mild, mode
model in which indicator variables were replaced with a single ordinal
OSA groups, respectively, and 0 in the non OSA group. OSA: obstructive
a Adjusted for body mass index and smoking.candidate as another factor causing lung injury.19
Although both comorbid obesity and smoking exposure
could affect plasma cytokine levels20 or the subjects’ lung
diffusion capacity,21,22 we showed that even after
adjustment for these confounders the association
between KL-6, pulmonary function impairment and OSA
remained significant, indicating the possible pathogenetic
role of OSA itself in lung injury.
KL-6 is a well-known biomarker for the diagnosis of IPF
and determination of the severity of this condition.23,24Model 2
usteda Unadjusted Adjusteda
0.18 b Z 0.22 b Z 0.18
0.02 p Z 0.004 p Z 0.02
0.04 b Z 0.07 b Z 0.02
0.67 p Z 0.39 p Z 0.80
e0.02 b Z 0.08 b Z 0.01
0.84 p Z 0.32 p Z 0.88
rate, and severe OSA as independent variables. Model 2: Linear
variable equal to the median AHI in the mild, moderate and severe
sleep apnea; SP-D: surfactant protein-D; CRP: C-reactive protein.
Table 3 Relationships between serum biomarker levels and pulmonary function and arterial blood gas data.
Serum KL-6 (U/ml) Serum CRP (mg/dl)
b coefficient p value b coefficient p value
VC (% predicted) 0.20 0.01 0.08 0.24
ERV (% predicted) 0.15 0.07 0.03 0.75
FVC (% predicted) 0.22 0.003 0.11 0.14
FEV1 (% predicted) 0.11 0.17 0.19 0.008
FRC (% predicted) 0.15 0.11 0.02 0.79
RV (% predicted) 0.05 0.53 0.12 0.11
TLC (% predicted) 0.14 0.049 0.18 0.01
DLCO (% predicted) 0.22 0.005 0.14 0.06
PaCO2 (kPa) 0.12 0.12 0.10 0.16
PaO2 (kPa) 0.13 0.11 0.11 0.16
A-aDO2 (kPa) 0.18 0.02 0.06 0.45
These analyses were adjusted by body mass index and smoking. VC: vital capacity; ERV: expiratory reserve volume; FVC: forced vital
capacity; FEV1: forced expiratory volume in 1 s; FRC: functional residual capacity; RV: residual volume; TLC: total lung capacity; DLCO:
diffusing capacity for carbon monoxide; PaCO2: arterial partial tension of carbon dioxide; PaO2: arterial partial tension of oxygen; A-
aDO2: alveolar-arterial oxygen tension difference.
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remains unclear, as a new topic in the field of IPF, recent
studies have reported a high prevalence of OSA in IPF
patients.16,25 Our findings may partially explain potential
mechanisms underlying this association and also provide
a warning that their combination as a comorbid condition
may additively worsen lung injury.
Serum levels of CRP did not correlate with the severity
of OSA independently of BMI in our study, which is consis-
tent with some reports.26,27 Obesity was shown to be
associated with chronic low-grade inflammation as indi-
cated by raised serum CRP levels.28 Considering that CRP
reflects obesity-related inflammation, it could be antici-
pated that CRP might have an association with reduced lung
volume due to obesity, particularly visceral adiposity.
However, notably, we found that elevated CRP levels were
significantly associated with worsened airflow limitation
and increased lung volume independently of obesity and
smoking, as contrasted with the significant relationship
between KL-6 and restrictive defects. Increased levels of
CRP also have been reported in obstructive and restrictive
lung disease,29 and were shown to be correlated with lower
levels of FEV1
3032 and a decline in FEV1.
33 Moreover,
a recent large-scale population-based study showed that
abdominal obesity was positively related to both obstruc-
tive and restrictive ventilatory patterns regardless of BMI.34
Thus, the inter-relationships among OSA, pulmonary func-
tion, obesity and inflammatory markers are complicated,
and further studies are needed.
Contrary to our hypothesis, unlike KL-6, SP-D was not
significantly associated with the severity of OSA, although
both are mainly produced by alveolar type II cells. Leakage
of these markers into the bloodstream may be dependent
on an alteration of production by alveolar type II cells and,
in addition, on the intensity, extent, and type of injuries
that precipitate the increase in alveolar wall perme-
ability.24 Thus, the magnitude of lung injury in patients
with OSA might be too subtle to increase the production of
SP-D by alveolar type II cells, although we did not assess the
local concentrations of SP-D in lung compartments. SP-D
was recently reported to be a promising lung-specificbiomarker in COPD.10 However, results of previous studies
suggested that KL-6 was a more discriminative biomarker
than SP-D in IPF and collagen vascular disease-associated
interstitial pneumonitis,24 idiopathic pulmonary alveolar
proteinosis35 or sarcoidosis.36 Madsen et al. reported that
SP-D was widely distributed in epithelial cells in a variety of
tissues and was not restricted to the respiratory system.37
Only a weak, though significant, relationship between
serum levels of KL-6 and SP-D in the present study indicates
that the blood level of these two cytokines may not
necessarily reflect the same pathological state of the
disease. Thus, although KL-6 appears to be superior to SP-D
in evaluating subclinical lung injury associated with OSA,
further study is needed to explain this discrepancy.
OSA is associated with significant morbidity and
mortality. Analyses of biomarkers in OSA have been
extensively performed in relation to its cardiovascular
effects through systemic inflammation.12 However, as well
as systemic inflammation, local inflammation or injury is
also implicated in the pathophysiology of OSA.38,39 Local
inflammation or injury has been assessed by surgical spec-
imens, exhaled breath condensate (EBC), induced sputum,
exhaled breath and oral air,38,39 but more studies with
a lung-specific biomarker in OSA are necessary for future
use of such biomarkers in clinical practice. A recent study
has also reported that the combination of two biomarkers,
SP-D (lung epithelial barrier injury) and interleukin-8
(inflammation and neutrophil chemotaxis), had significant
prognostic value, reflecting the two important pathoge-
netic pathways of acute lung injury.40 Thus, KL-6 in asso-
ciation with a systemic biomarker such as CRP might
provide complementarily useful information in assessing
OSA.
In our study, there was a significant positive relationship
between AHI and smoking. Airway inflammation and
damage due to cigarette smoke could alter the mechanical
and neural properties of the upper airway and increase its
collapsibility during sleep, which may be related to sleep
apnea.41
The prevalence of OSA in our population was high
(88.2%). Since all participants in our study were referred to
944 K. Aihara et al.our sleep unit with suspicious symptoms, there was a high
clinical probability of OSA among these patients. Actually,
the diagnostic rates in some other sleep laboratories were
comparable to ours.42e44
The present study has some limitations. First, as we did
not directly assess local expressions of KL-6 in the lung and
alveolar wall permeability in OSA patients, our results
cannot clearly establish the presence of lung injury in OSA.
Measurements of KL-6, albumin concentration or cell count
in bronchoalveolar lavage fluid, EBC or induced sputum
would provide additional information and supporting
evidence for our suggestions regarding the implications of
these results. Second, as we did not assess serum biomarker
levels after treatment of OSA, we could not confirm the
specific association between OSA and serum biomarkers.
Third, as the values of AHI and biomarkers tended to be
skewed, we tried to transform them logarithmically.
However, in 57 patients the CRP values could not be
transformed logarithmically (CRP value was ‘0’). We then
made calculations using absolute values. However, signifi-
cance of the result between KL-6 and AHI remained even
after logarithmic transformation (r Z 0.20, p Z 0.01).
In summary, serum levels of KL-6 but not SP-D were
correlated with subclinical lung injury associated with OSA
independently of obesity or smoking, and KL-6 could be
a potential candidate as a lung-specific biomarker in OSA.
KL-6 values may pathologically reflect epithelial and endo-
thelial injury in the alveolus and pulmonary function
impairment in OSA. This is in contrast to CRP, which is a well-
studied systemic biomarker and may preferably cause an
obstructive defect. A combination of two different types of
biomarkersmight be complementary and be superior to each
biomarker alone from a pathogenesis perspective.
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